title: Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
abstract: The antibacterial activity of tazobactam-piperacillin was compared with that of sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone and piperacillin against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections. Tazobactam-piperacillin showed a broad antibacterial spectrum against gram-negative and gram-positive bacteria. The minimum inhibitory concentrations (MIC90) of tazobactam-piperacillin were 6.25 micrograms/ml against Escherichia coli, 1.56 micrograms/ml against Proteus mirabilis, 3.13 micrograms/ml against Proteus vulgaris, 6.25 micrograms/ml against methicillin-susceptible Staphylococcus aureus, and 6.25 micrograms/ml coagulase-negative methicillin-susceptible staphylococci. Against all beta-lactamase-producing bacteria tested the antibacterial activity of tazobactam-piperacillin was at least 4- to 64-fold stronger than that of piperacillin, clavulanic acid-ticarcillin, and sulbactam-ampicillin, and similar to or greater than that of sulbactam-cefoperazone except for E. coli.
authors.affiliation: Department of Microbiology, School of Medicine, Fukuoka University, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Nomura
authors.forename: H
authors.initials: H
authors.lastname: Hanaki
authors.forename: A
authors.initials: A
authors.lastname: Nagayama
mesh_terms: D000667:Ampicillin / Q000494:pharmacology; D002438:Cefoperazone / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000494:pharmacology; D015169:Colony Count, Microbial; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000382:microbiology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D010406:Penicillins / Q000494:pharmacology; D010878:Piperacillin / Q000494:pharmacology; D012189:Retrospective Studies; D013407:Sulbactam / Q000494:pharmacology; D000078142:Tazobactam; D013982:Ticarcillin / Q000494:pharmacology; D014551:Urinary Tract / Q000382:microbiology*; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology*; D065093:beta-Lactamase Inhibitors
chemical_list: D002511:Cephalosporins; D002969:Clavulanic Acids; D004791:Enzyme Inhibitors; D010406:Penicillins; D065093:beta-Lactamase Inhibitors; D019818:Clavulanic Acid; D000667:Ampicillin; D002438:Cefoperazone; D010397:Penicillanic Acid; D013982:Ticarcillin; D013407:Sulbactam; D000078142:Tazobactam; D010878:Piperacillin